Brian N. Cherry
CIK: 0001290922
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Sep 4, 2026ATRA
Atara Biotherapeutics, Inc.
Purchase(P)Direct104.2K shares at avg. $9.60$1000K - Jun 11, 2026ATRA
Atara Biotherapeutics, Inc.
Award(A)Direct24K shares- - Jan 12, 2026ZYME
Zymeworks Inc.
Award(A)DirectStock Option (Right to Buy)
23K shares- - Jan 12, 2026ZYME
Zymeworks Inc.
Award(A)DirectRestricted Stock Unit
15.4K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 4, 2026 |  ATRA Atara Biotherapeutics, Inc. | Purchase(P) | 104,166 | $9.60 | $999,994 | Direct |
| Jun 11, 2026 | ATRA Atara Biotherapeutics, Inc. | Award(A) | 24,000 | - | $0 | Direct |
| Jan 12, 2026 |  ZYME Zymeworks Inc. | Award(A) Stock Option (Right to Buy) | 23,000 | - | - | Direct |
| Jan 12, 2026 | ZYME Zymeworks Inc. | Award(A) Restricted Stock Unit | 15,400 | - | - | Direct |
1-4 of 4 transactions
About Cherry Brian N
Cherry Brian N (SEC CIK 0001290922) files insider reports with the SEC as Director of Atara Biotherapeutics, Inc. (ATRA) and Director of Zymeworks Inc. (ZYME).
Signal8 holds 5 ownership filings by Cherry Brian N (2 Form 3, 3 Form 4), filed between Jan 13, 2026 and Sep 4, 2026. Those filings report 4 transactions, from Jan 12, 2026 to Sep 4, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Cherry Brian N's filings is in THOUSAND OAKS, CA.
Recent filings by Cherry Brian N
Other insiders filing for Atara Biotherapeutics, Inc. (ATRA)
- Nguyen AnhCo, President and CEO
- Redmile Group, LLC, Director
- Sarney Kevin G, Interim CFO
- HEIDEN WILLIAM K, Director
- Fust Matthew K, Director
- Ciongoli Gregory Austin, Director